Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency

Submission date	Recruitment status	Prospectively registered
30/09/2005	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2005	Completed	Results
Last Edited	Condition category	Individual participant data
02/02/2017	Circulatory System	[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Kevin Burnand

Contact details

Guy's and St Thomas' NHS Foundation Trust
General, Vascular and Colorectal Surgery Department
F01 North Wing
St Thomas' Hospital
Lambeth Palace Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 2570
Kevin.burnand@kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0013146069

Study information

Scientific Title

Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency: a randomised controlled trial

Study objectives

- 1. Is haemosiderin a reliable marker for venous insufficiency?
- 2. Does the inhibition of matrix metalloproteinase play any role in the healing of ulcer?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Cardiovascular: Venous ulcers

Interventions

Patients will be randomised into either treatment or control group. Each group will be matched according to ulcer size. The treatment group will take two daily 100mg of doxycycline and the patients in the control group will take matched placebo tablets. A biopsy from the ulcer will be obtained before the start of the study and at 8 weeks. Sample will be used to determine the Matrix Metalloproteinase (MMPs) level.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Haemosiderin

Primary outcome measure

Ulcer sizes, complete or incomplete healing

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/09/2003

Completion date

01/12/2007

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

60 patients will be recruited from the venous ulcer out patients clinic at St Thomas' Hospital

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/09/2003

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Guy's and St Thomas' NHS Foundation Trust
London
United Kingdom
SE1 7EH

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

Guy's and St. Thomas' NHS Foundation Trust (UK)

Funder Name

Own Account - NHS R&D Support Funding

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration